Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.
Internal U.S. Army memo flags 'fundamental security' vulnerabilities in a key battlefield communications network, raising contract concerns.
Shares of the recently-listed marine fuel provider hit all-time lows on massive volume as the market reacts to unspecified executive shifts.
Blaze at the massive El Segundo facility, a key fuel supplier for Southern California, raises concerns over potential price impacts.
A notorious ransomware group claims to have stolen sensitive corporate data, putting Oracle's reputation and customer security under scrutiny.
Settlement with Dr. Reddy's Laboratories shields key drugs NEXLETOL and NEXLIZET from generic competition until 2040, boosting investor confidence.
With a potential market of 128 million in the U.S., analysts see blockbuster potential for the new presbyopia treatment.